Nanovibronix, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
ENvue Medical, Inc. has entered into a $50 million committed equity facility with an institutional investor to provide flexible capital for working capital and preferred stock redemption.
ENvue Medical announces board changes with two resignations and the appointment of two new directors, including a new Board Chairman.
ENvue Medical has received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement, potentially leading to delisting.
ENvue Medical, Inc. announced an amendment to CEO Doron Besser's employment agreement and the appointment of David Johnson as Chairman of the Board, detailing their compensation and equity grants.
ENvue Medical, Inc. amended its Series H Convertible Preferred Stock terms, removing the floor price in exchange for a $2.5 million additional investment from holders.
ENvue Medical, Inc. has amended its 2024 Long-Term Incentive Plan to incorporate Israeli tax law compliance and reflect recent corporate updates.
ENvue Medical, Inc. announced an amended employment agreement for CEO Doron Besser, M.D., increasing his salary and equity, and appointed Nicole Fernandez-McGovern as Interim CFO following Stephen Brown's departure.
NanoVibronix, Inc. announced a corporate name change to ENvue Medical, Inc. and a ticker symbol change to FEED, effective December 12, 2025, to align with its strategic focus on the ENvue feeding-tube placement system.
NanoVibronix stockholders approved a new board slate and significantly increased shares for its long-term incentive plan at the 2025 Annual Meeting.
NanoVibronix announces a strategic shift to focus on its ENvue feeding-tube placement system, planning a rebranding to ENvue Medical and exploring alternatives for legacy assets.
Four directors, including key committee members, are retiring from NanoVibronix's Board for personal reasons ahead of the 2025 Annual Meeting.
NanoVibronix, Inc. announced a registered direct offering of common stock and prefunded warrants, raising approximately $1.8 million net for working capital and debt repayment.
NanoVibronix, Inc. announced a change in its independent registered public accounting firm and an amended employment agreement for its Chief Financial Officer, Stephen Brown.
NanoVibronix, Inc. will effect a 1-for-10 reverse stock split of its common stock, effective August 11, 2025, to maintain Nasdaq listing.
NanoVibronix, Inc. announced the appointment of Rita Silberberg as Executive Vice President of Finance, Chief Accounting Officer, and Corporate Secretary, effective July 24, 2025.
NanoVibronix, Inc. has completed an initial private placement raising $8 million through the sale of Series H Convertible Preferred Stock and warrants, with proceeds earmarked for debt redemption and working capital.
NanoVibronix, Inc. stockholders approved a reverse stock split proposal, allowing the Board discretion to implement a ratio between 1-for-2 and 1-for-50, and an adjournment proposal at a special meeting held on July 17, 2025.
8-K: NanoVibronix Adjourns Special Stockholder Meeting Due to Lack of Quorum, Reschedules for July 17
NanoVibronix, Inc. adjourned its Special Meeting of Stockholders on July 11, 2025, due to an absence of a quorum and will reconvene the meeting virtually on July 17, 2025.
NanoVibronix, Inc. filed a certificate of correction to amend a typographical error in the Floor Price definition for its Series G Convertible Preferred Stock, changing it from $1.02 to $1.91.
NanoVibronix, Inc. announced the retirement of CEO Brian Murphy and the immediate appointment of Doron Besser, CEO of its recently acquired subsidiary ENvue Medical Holdings, LLC, as the new Chief Executive Officer.
NanoVibronix announces the pricing of a $10 million underwritten public offering of Series G Convertible Preferred Stock and warrants to purchase common stock.
ENvue Medical Holdings, a subsidiary of NanoVibronix, Inc., has entered into a promissory note agreement for $360,000 with Alpha Capital Anstalt, guaranteed by NanoVibronix.
Aurora Cassirer resigned from the board of directors of NanoVibronix, Inc., effective April 1, 2025.
An independent study published in The Australian and New Zealand Continence Journal highlights the effectiveness of NanoVibronix's UroShield device in preventing CAUTIs and reducing healthcare costs.
NanoVibronix implements a 1-for-11 reverse stock split effective March 13, 2025, to comply with Nasdaq listing requirements.
NanoVibronix, Inc. announces the approval of key proposals, including a reverse stock split and share issuance, at its special meeting of stockholders held on February 24, 2025.
NanoVibronix finalizes the acquisition of ENvue Medical Holdings, aiming to strengthen its market position in enteral feeding technology and therapeutic medical devices.
NanoVibronix has entered into a securities exchange agreement, issuing new shares and warrants in exchange for an existing warrant.
NanoVibronix has completed the first phase of a UroShield study at the University of Michigan, while also facing potential delisting from Nasdaq due to non-compliance with listing rules.
NanoVibronix, Inc. held its 2024 annual meeting where stockholders approved the 2024 Long-Term Incentive Plan and elected eight directors.